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Azoreductases are well known for azo pro-drug activation by gut flora. We show that azoreductases have a
wider role in drug metabolism than previously thought as they can also reduce and hence activate
nitrofurazone. Nitrofurazone, a nitroaromatic drug, is a broad spectrum antibiotic which has until now
been considered as activated in bacteria by nitroreductases. The structure of the azoreductase with
nitrofurazoneboundwassolvedat2.08 A ˚ andshowsnitrofurazoneinanactiveconformation.Basedonthe
structural information, the kinetics and stoichiometry of nitrofurazone reduction by azoreductase from
P. aeruginosa, we propose a mechanism of activation which accounts for the ability of azoreductases to
reduce both azo and nitroaromatic drugs. This mode of activation can explain the cytotoxic side-effects of
nitrofurazone through human azoreductase homologues.
A
zoreductases are a group of NAD(P)H dependent flavoenzymes that have been identified in a range of
bacterial species found in the gut including E. coli
1 and P. aeruginosa.
2 Members of this family are also
found in humans where they are known as NAD(P)H quinone oxidoreductases.
3 The importance of
azoreductasesindrugmetabolisminthegutiswellknownforazodrugsusedtotreatinflammatoryboweldisease
e.g.balsalazide.
4Datahaveshownthattheseenzymescanreduceanumberofotherclassesofsubstrateincluding,
quinones
1, 5 and nitroaromatics.
6 As a result of the diverse substrate specificity profile it is suggested that the role
of azoreductases in drug metabolism may be wider than originally thought.
Nitroaromatic groups are found in a range of drugs currently on the market including the anti-inflammatory
nimuselide and the parkinson’s disease treatment tolcapone. A common feature of some nitroaromatic drugs is
hepatotoxicity resulting from reduction of the nitro group.
7 Nitrofurazone was selected as an example of a
nitroaromatic drug to study the mechanism of nitroreduction by azoreductases and their human homologues
NAD(P)H quinone oxidoreductases. Nitrofurazone (Fig. 1) is a topical antibiotic mainly used to treat burns and
skin grafts. Nitrofurazone is part of the 5-nitrofuran family, which are potent antibiotics, active against both
Gram-positiveandGram-negativebacteria.Membersofthe5-nitrofuranfamilyarebeingdevelopedastherapies
for multidrug resistant bacteria e.g. M. tuberculosis.
8 Nitrofurazone and the other members of this family have a
common mode of action that requires intracellular activation by nitroreductases. As a result, mutations within
two nitroreductases known as nitrofuran sensitivity genes A and B (NfsA and B) from E. coli provide nitrofur-
azoneresistance.
9Ashumanslacknitroreductasessuchasthese,themajorityofnitroreductionwillbecarriedout
by NAD(P)H quinone oxidoreductases.
10 Activation by nitroreductases results in four electron reduction of the
nitro group to a reactive hydroxylamine metabolite
11 that in combination with the nitroso oxidation product
causes DNA damage.
12
Three azoreductases from P. aeruginosa, paAzoR1, paAzoR2 and paAzoR3, have been extensively charac-
terised.
2, 5, 13, 14Arecentstructuralstudyhasprovidedinsightintothemechanismbywhichazoreductasesactivate
azo drugs,andalsoexplains theirability toreducebothazoandquinonesubstrates.
13Theaforementioned ability
of azoreductases to act as nitroreductases indicates they may also reduce nitrofurazone.
6, 15
The structure of E. coli NfsB bound to nitrofurazone has been solved
11 the structure showed nitrofurazone
bound in what the authors described as aninactive conformation within the enzyme active site. Inorder for their
proposed mechanism of reduction to be correct nitrofurazone has to reverse its binding orientation as a result of
FMNbeinginthereducedstate.Theworkdescribedinthismanuscript demonstratesthatazoreductasescanalso
reducenitrofurazoneanddescribesthekineticsofnitrofurazonereductionbypaAzoR1aswellasthestructure of
nitrofurazone bound to paAzoR1 in an active conformation. Based on this structure, a putative mechanism is
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also applicable to the mechanism of reduction of nitrofurazone and
other nitroaromatic drugs by bacterial azoreductases and by their
human homologues.
Results
NitrofurazoneisreducedbypaAzoR1.Nitrofurazonewasshownto
bereducedbypaAzoR1,apparentKmandVmaxvalueswereobtained
via Lineweaver-Burk plots. The apparent Km f o rp a A z o R 1w a s1 5 . 76
1.6 mM and the Vmax was 9.8 6 0.6 mM.s
21.mg of enzyme
21.V i a
equations (1) and (2) the rates of nitrofurazone reduction
and NADPH oxidation were obtained simultaneously under the
conditions described in the materials and methods. The
simultaneous rates obtained during nitrofurazone reduction were
3.12 6 0.06 mM.s
21.mg of enzyme
21 for nitrofurazone and 5.76 6
0.25 mM.s
21.mg of enzyme
21 for NADPH this gives an estimate for
the molar ratio of the reaction of approximately 2 moles NADPH
oxidation per mole nitrofurazone reduction. Mass spectroscopy data
obtained from a completed reaction carried out in ammonium
bicarbonate gave a major peak at 184 Da (Supp. Fig. 1).
Structure of paAzoR1 binding nitrofurazone. The structure of
paAzoR1 binding to nitrofurazone was solved at a resolution of
2.08 A ˚ with final Rfree and Rwork values of 20.4% and 16.1%
respectively and with good stereochemistry (Table 1). No
significant conformational changes were observed between the
structures of paAzoR1 bound to methyl red and paAzoR1 bound
to nitrofurazone (RMSD on carbon a positions 0.23 A ˚). No
significant movements of the amino acid side chains within the
active site were observed when the structures were compared.
Clear positive difference density was visible for the nitrofurazone
bound within the active site after a single round of refinement in
PHENIX (Fig. 2A). Nitrofurazone was built into the density initially
in one orientation, however upon further refinement it became clear
there was density for nitrofurazone in two overlapping orientations.
In both orientations the nitro group of nitrofurazone is positioned
above the N5 of FMN in contrast to the orientation observed in the
structure of NfsB bound to nitrofurazone where the nitro is 7.7 A ˚
from the N5 (Fig. 3F
11). Nitrofurazone binds in an overlapping con-
formation to that previously observed for balsalazide bound to
paAzoR1 (Fig. 2B
13) and methyl red bound to the Y131F mutant of
paAzoR1,
14 as a result it makes many of the same interactions. The
furan rings of both conformers overlap the salicylate ring of balsa-
lazide in the corresponding structure and the polar tail of nitrofur-
azoneoverlapswiththepositionoftheazobondofbalsalazideaswell
as partially overlapping the 4-aminobenzoyl-b-alanine ring of balsa-
lazide (Fig. 2B). As the furan ring forms weaker p2p stacking
interactions, than the benzene rings of balsalazide, the furan ring
binds at an angle to the plane of the FMN. As well as forming p-p
stacking interactions with FMN, nitrofurazone forms hydrophobic
interactions with Tyr131, Phe100, Phe151 and Phe173, while the
nitro group points into a water filled channel close to the side chain
of Asn99.
Discussion
paAzoR1 binds nitrofurazone with a significantly lower Km than azo
compounds
14 while the rate of reduction is also lower. The slow rate
ofreductionislikelytobeduetocompetition between nitrofurazone
andNADPHforbindingtotheactivesite.DuetotheveryhighKmof
NADPH (,1.2 mM
14) the tight binding of nitrofurazone causes
substrate inhibition. Apparent Vmax is higher than that previously
observed in R. sphaeroides azoreductases (0.23 mM.s
21.mg of
enzyme
21).
16 The rate of nitroreduction by paAzoR1 is significantly
slowerthaninnitroreductasessuchasNfsB(kcat2.3 s
21forpaAzoR1
compared to 225 s
21 for NfsB
11) suggesting that in bacteria the
majority of activation is carried out by nitroreductases.
The calculated molar ratio of approximately 2:1 for the rate of
NADPHoxidationtonitrofurazonereductionisin-linewiththedata
that were obtained from Electrospray ionisation, time of flight mass
spectroscopy (ESI-TOF-MS Sup. Fig. 1B). The mass spectroscopy
data agree with previously published data
11 that show the final reac-
tion product is consistent with the hydroxylamine reductive meta-
bolite of nitrofurazone (MW 5 184 Da).
As when determining the mechanism of reduction of azo drugs,
13
thetautomericstateofnitrofurazoneboundtotheenzymeisimport-
ant, the tautomer that binds paAzoR1 can be determined from the
structure. Nitrofurazone can exist in two tautomers (Fig. 1) that are
broadly equivalent to the azo and hydrazo tautomers of balsalazide.
Based on previous work on this enzyme, one might expect that the
azoformwouldbethemorelikelysubstrateasithasamorequinone-
like ring.
13The azo form of the compound would be planar due to its
extensive conjugated system, the density for nitrofurazone in the
structure however is not planar (Fig. 2A) and this is more in keeping
with the hydrazo tautomer where one of the nitrogen atoms is sp
3
hybridised. This hypothesis is in agreement with the proposed con-
formation ofthe boundbalsalazide with wherethe ‘‘azo’’bond isin a
similar conformation (Fig. 2B).
In the structure of NfsB binding to nitrofurazone,
11 nitrofurazone
is observed to bind within the active site in a non-planar conforma-
tion(similar tothat observed inthe structure with paAzoR1) with its
nitro group bound 7.7 A ˚ from the N5 of FMN. In this structure
nitrofurazone is anchoredwithin the active sitevia anetwork ofnine
Table 1 | ProcessingandrefinementstatisticsforpaAzoR1binding
nitrofurazone.
paAzoR1 nitrofurazone
Space Group P3121
a, b, c (u) 90, 90, 120
a, b, c (A ˚) 82.20, 82.20, 108.46
Processing Statistics
Resolution Range (A ˚) 29.76-2.08
Unique reflections
a 25,761 (1,794)
Rmerge
a 0.061 (0.766)
,I/s(I).
a 18.6 (2.0)
Completeness %
a 99.6 (95.3)
Multiplicity
a 5.4 (5.2)
Refinement Statistics
Rwork % 16.07
Rfree % 20.35
RMS bond angle (u) 0.98
RMS bond length (A ˚) 0.007
aNumbers in parentheses are for the highest resolution shell.
Figure 1 | Structure of nitrofurazone. Figure showing the two nitrofurazone tautomers that occur in equilibrium in solution.
www.nature.com/scientificreports
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the ribose chain of FMN and the side chains of Glu165 and Asn71.
This is in sharp contrast to the entirely hydrophobic interactions
nitrofurazone makes within the active site of paAzoR1. As the bind-
ing conformation observed in the structure with NfsB is incom-
patible with the proposed mechanism of reduction it was
speculated that when binding to the reduced enzyme, nitrofurazone
binds in the reverse orientation, which would mean it is in a similar
orientation to that observed in the paAzoR1-nitrofurazone strucu-
ture. High resolution structural data (1.9 A ˚) from a closely related
nitroreductase (88% identical – all active site residues are conserved)
from E. cloacae in both the reduced and oxidised states show that
reduction of FMN has little effect on surrounding active site resi-
dues.
17 Lower resolution (2.5 A ˚) structures of the reduced and oxi-
disedformsofNfsBarealsoavailableandshowthereisnosignificant
conformational changes in the active site residues as a result of FMN
reduction.
18 It is therefore unlikely that reduced NfsB would bind
nitrofurazone in a different conformation. The large number of
interactionswhichareinvolvedwiththepositioningofnitrofurazone
in the conformation observed in the oxidised NfsB structure would
Figure 3 | Comparisonoftheoverallstructures (A–C)andnitroaromaticbinding(D–F)ofpaAzoR1(A,D), hNQO2(B,E)andNfsB(C,F). (A–C)The
overallstructure ofthedimeric formsofeachofthethree proteins. Inallthree panelsmonomer Aisingreen andB isinturquoise. (D–F)Adetailed view
of nitroaromatic drug binding within the active site of the enzymes (nitrofurazone in paAzoR1 and NfsB and CB1954 in hNQO2). In all panels the
flavincofactorisinyellow(FMNforpaAzoR1andNfsB,FADforhNQO2).TheNitroaromatic drugisinbrowninpanelsD–F.ThestructureofhNQO2
bound to CB1954 is from PDB 1XI2
20 and the structure of NfsB bound to nitrofurazone is from PDB 1YKI.
11
Figure 2 | Binding of nitrofurazone to paAzoR1. A) The binding of nitrofurazone in its two alternate conformers are shown with brown carbon atoms.
The FMN is shown with yellow carbon atoms, both conformations of nitrofurazone are shown with brown carbon atoms. Important side chains are
labelled.Bluemeshistherefined2Fo-Fcmapcontouredat1s,whileblackmeshisunbiasedFo-Fcmapat2.2s.Theblacksphererepresentsaboundwater
molecule.(B)ComparisonofbalsalazideandnitrofurazonebindingtopaAzoR1.Colouringofnitrofurazoneisasin(A)andbalsalazideisinpurple.This
figure was produced in Pymol v1.1.
31
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 63 | DOI: 10.1038/srep00063 3mean that most likely alternate conformations will be energetically
less favourable.
The proposed mechanism for nitroreduction, based on the azo
tautomer being reduced, is shown in Fig. 4. Reduction reactions
carried out by azoreductases proceed via a Bi-Bi ping-pong mech-
anism
1, 14 therefore as occurs during azoreduction,
13 substrate bind-
ing is preceded by NADPH binding. While bound to paAzoR1,
NADPH transfers a hydride ion to the N5 of FMN which becomes
FMNH
2. NADPH is subsequently displaced bynitrofurazone which
accepts the hydride from FMNH
2 (Fig. 4A). The position of the
nitrogen of the nitro group of each conformer of nitrofurazone
within 3.6 A ˚ of the N5 atom of FMN suggests that this is the target
for hydride transfer. As the nitrogen atom of a nitro group is posi-
tively charged this also makes it a good candidate for transfer of the
negatively charged hydride. To complete the reduction reaction a
proton is accepted from the water molecule (Fig. 4A) which is stably
bound to the protein within 3 A ˚ of the nitro group of nitrofurazone
(Fig. 2A). The reduction takes place twice according to the same
mechanism, in order to get complete formation of the hydroxyl-
amine species, therefore, a double Bi-Bi ping pong mechanism can
also be proposed for nitrofurazone reduction in paAzoR1.
In addition it was noted that in the structure of paAzoR1 binding
balsalazide, the oxygen of the quinoneimine tautomer of balsalazide
is,2.7 A ˚ fromtheketoneoftheAsn99sidechain.Inthestructureof
paAzoR1bindingnitrofurazoneoneoftheoxygenatomsofthenitro
group is a similar distance from the carbonyl of Asn99. This posi-
tioning would allow hydrogen bond formation after reduction of
either substrate which may help to stabilise the reduced form of
the compound and thus may facilitate hydride transfer.
Nitrofurazone is known to be carcinogenic in mammals.
19 Unlike
bacteria, humans have no homologues of NfsA and NfsB, as a result
the majority of nitrofurazone activation in humans is proposed to
occur via azoreductase-like enzymes. Humans have two azoreduc-
tase homologues, NAD(P)H quinone oxidorductase (hNQO) 1 and
2.Althoughbacterialazoreductases shareminimalsequence similar-
ity with hNQO1 and hNQO2
13 they are structurally related (Fig. 3A
and B
20, 21) and carry out many of the same reactions.
3 Both hNQO1
and hNQO2 have been shown to activate the anti-tumour pro-drug
CB1954 via nitroreduction.
10 Activation of nitrofurazone by these
enzymes may result in the carcinogenic properties in mammals
and may be the cause of contact dermatitis experienced with nitro-
furazone. The structure of hNQO2 binding CB1954 (Fig. 3E – PDB:
1XI2
20)showsthenitrogroupthatisreduced,bindswiththenitrogen
within3.6 A ˚ oftheN5ofFMNinasimilarpositiontothenitrogroup
of nitrofurazone bound to paAzoR1. As a result it is proposed that
other nitroaromatics are reduced by azoreductases via the same
mechanism as is described here for nitrofurazone.
Methods
AllreagentswereobtainedfromSigma-Aldrich(Poole,UK)unlessotherwisespecified.
Enzymology. Recombinant paAzoR1 was prepared as described previously.
2 Unless
otherwise stated assays were carried out in 96-well format in a reaction volume of
100 mL using a Fluostar Omega plate reader from BMG labtech (Aylesbury, UK)
typicallyusing10 mgpaAzoR1perwell,750 mMNADPHandvaryingconcentrations
of nitrofurazone in 20 mM Tris-HCl pH 8.0, 100 mM NaCl.
In order toestimate the stoichiometry of the enzymatic reduction of nitrofurazone
by paAzoR1, the following reaction was carried out: 50 mM nitrofurazone, 400 mM
NADPH, 10 mg paAzoR1. Both the oxidation of NADPH and the reduction of
nitrofurazone were simultaneously followed spectrophotometrically at 340 nm and
405 nmrespectively.Themolarextinctioncoefficientofeachspecieswasdetermined
at each lmax (eNADPH, 340 3,300 M
21cm
21, eNADPH, 405 0M
21cm
21, eNitrofurazone, 405
10,800 M
21cm
21 and eNitrofurazone, 340 9,500 M
21cm
21). Initial velocities were esti-
mated via the following equations:
equation 1 ðÞvi (340 nm)~
LOD(340 nm)
Lt
~‘: L½NADPH 
Lt
eNADPH, 340z
L½nitrofuraz one 
Lt
enitrofuraz one, 340

equation 2 ðÞvi (405 nm)~
LOD(405 nm)
Lt
~‘: L½nitrofuraz one 
Lt
enitrofuraz one, 405

As e NADPH 405 is 0, it is straightforward to determine the rate of nitrofurazone
reduction
L½nitrofurazone 
Lt
. This value is used to estimate
L½NADPH 
Lt
in
equation (1). The ratio of
L½NADPH 
Lt
to
L½nitrofurazone 
Lt
provides an estimate for
the ratio of NADPH oxidation to nitrofurazone reduction.
Identification of the products of nitrofurazone reduction. Identification of the
finalreductionproductswascarriedoutviaESI-TOF-MS.Thereducednitrofurazone
wasproducedviathefollowingreaction:25 mMnitrofurazone,0.5 mMNADPHand
100 mg paAzoR1 in a final volume of 1 mL containing 25 mM ammonium
bicarbonate pH 7.9 (,0.5 mM NaCl). The reaction was monitored at OD405 on a
Hitachi (Mannheim, Germany) U-2001 spectrophotometer and allowed to
proceed to .98% completion. paAzoR1 was removed via a Sartorius (Ashtead, UK)
3 kDa molecular weight cutoff vivaspin centrifugal concentrator. The reaction
mixture containing reduced nitrofurazone was lyophilised with a Lab mode (Milton
Keynes, UK) ScanVac, before resuspension in 1 mL methanol. ESI-TOF-MS was
carried out on a Waters (Elstree, UK) micromass mass spectrometer in negative
ion mode.
Figure 4 | Mechanism for nitrofurazone reduction. (A) First round of nitrofurazone reduction. (B) Second round of nitrofurazone reduction resulting
inhydroxylamine formation.Theprotoninboth(A)and(B)islikelytobedonatedbyastablyboundwatermoleculeobservedinthestructure(Fig.2A).
Before (A) and between (A) and (B) NADPH binds to paAzoR1 and transfers a hydride to FMN before being replaced by nitrofurazone.
www.nature.com/scientificreports
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solution of 23 mg.mL
21 paAzoR1 in 20 mM Tris-HCl pH 8.0 with 2 mM
nitrofurazone and incubated for an hour before being washed with 20 mM Tris-HCl
pH 8.0toremoveDMSO.Crystalsgrewisomorphouslyunderthesameconditionsas
previously described,
2 briefly 2 mL protein complex was mixed with 2 mL 1.6 M
(NH4)2SO4 0.1 M HEPES pH 7.5 in sitting drop format. Data for paAzoR1-
nitrofurazone were collected at beamline I02 at the Diamond Light Source (Oxon,
UK)withaQuantumADSCdetector.DatawereintegratedviaXDS,
22andscaledand
merged with SCALA
23 both were run as part of xia2.
24 The structure was solved with
the program PHASER,
25 using the structure of paAzoR1 stripped of its ligands (PDB:
2V9C
2) as the search model. The atomic model was rebuilt and refined with Coot,
26
Refmac5.5
27andPHENIX.
28Initialtranslation,librationandscrew(TLS)parameters
were determined with the program TLSMD
29 and TLS refinement was performed
with PHENIX. Restraints for nitrofurazone were generated in eLBOW. Water
molecules were added with PHENIX and Coot. The final model was validated via
MolProbity
30 and all residues were shown to lie within the allowed regions of the
Ramachandran plot (97.8% in the preferred region and 2.2% in the allowed region).
Data collection and refinement statistics are shown in table 1. The structure was
deposited in the protein data bank (PDB ID: 3R6W).
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